Clinical and pharmacologic correlations in cyclosporine-induced gingival hyperplasia.
Cyclosporine-induced gingival hyperplasia was investigated in a clinical study of 100 patients over a period of 2 1/2 years. Seventy percent of the patients exhibited at least mild gingival hyperplasia. For doses within the therapeutic range, no direct correlation was found between the oral dose or the serum trough concentration of cyclosporine and the severity of gingival hyperplasia. The presence of dental plaque was found to be related to the presence of gingival hyperplasia, but only a weak correlation existed between the abundance of plaque and the severity of gingival hyperplasia. Children and especially adolescents had a greater risk of developing cyclosporine-induced gingival hyperplasia than adults had. In 21 patients followed for 1 to 18 months after cessation of cyclosporine therapy, induced gingival hyperplasia was found to be clinically reversible.
Daley
T D
TD
Wysocki
G P
GP
Day
C
C
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002648:Child; D003524:Cyclosporins / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D004334:Drug Administration Schedule; D005260:Female; D005885:Gingival Hyperplasia / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D008297:Male; D009910:Oral Hygiene; D012737:Sex Factors; D013997:Time Factors
D003524:Cyclosporins